Do glucagon-like peptide-1 based therapies alter the risk of late-onset inflammatory bowel disease?

Autor: Christensen HS; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, A.C. Meyers Vænge 15, 2450 Copenhagen, Denmark., Andersen DV; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, A.C. Meyers Vænge 15, 2450 Copenhagen, Denmark., Jess T; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, A.C. Meyers Vænge 15, 2450 Copenhagen, Denmark; Department of Gastroenterology & Hepatology, Aalborg University Hospital, Mølleparkvej 4, 9000 Aalborg, Denmark., Allin KH; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, A.C. Meyers Vænge 15, 2450 Copenhagen, Denmark; Department of Gastroenterology & Hepatology, Aalborg University Hospital, Mølleparkvej 4, 9000 Aalborg, Denmark. Electronic address: allin@dcm.aau.dk.
Jazyk: angličtina
Zdroj: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Apr; Vol. 56 (4), pp. 713-715. Date of Electronic Publication: 2024 Jan 27.
DOI: 10.1016/j.dld.2024.01.183
Abstrakt: Competing Interests: Conflict of interest Tine Jess has served as a consultant to Ferring. The authors have no other conflicts of interest to declare.
Databáze: MEDLINE
Externí odkaz: